XML 41 R56.htm IDEA: XBRL DOCUMENT
v2.4.0.8

License and Collaboration Agreements - Additional Information (Detail) (USD $) In Millions, unless otherwise specified | 12 Months Ended | 0 Months Ended |  | 0 Months Ended |  |  | 3 Months Ended | 0 Months Ended |  | 1 Months Ended | 3 Months Ended | 12 Months Ended | 1 Months Ended | 2 Months Ended |  | 1 Months Ended | 3 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 3 Months Ended |  | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 31, 2013 | Sep. 25, 2013 Naloxegol [Member] | Dec. 31, 2013 Naloxegol [Member] US and EU Commercial Launch [Member] | Sep. 16, 2013 AstraZeneca AB [Member] | Sep. 16, 2013 AstraZeneca AB [Member] January 15, 2015 [Member] | Sep. 16, 2013 AstraZeneca AB [Member] Second Installment [Member] | Sep. 16, 2013 AstraZeneca AB [Member] January 15, 2017 [Member] | Sep. 16, 2013 AstraZeneca AB [Member] January 15, 2018 [Member] | Dec. 31, 2013 AstraZeneca AB [Member] FDA Acceptance [Member] | Dec. 31, 2009 AstraZeneca AB [Member] Naloxegol (NKTR-118) and Naloxegol Fixed-dose Combination Program (NKTR-119) [Member] Upfront Payment Arrangement [Member] | Sep. 16, 2013 AstraZeneca AB [Member] Naloxegol [Member] | Dec. 31, 2013 AstraZeneca AB [Member] Naloxegol [Member] | Dec. 31, 2013 AstraZeneca AB [Member] Naloxegol [Member] Pre-approval Cardiovascular Safety Study Not Required [Member] | Dec. 31, 2013 AstraZeneca AB [Member] Naloxegol Fixed-dose Combination Program [Member] | Dec. 31, 2009 Roche [Member] License Extension Option [Member] | Dec. 31, 2013 Roche [Member] MIRCERA [Member] | Dec. 31, 2013 Roche [Member] MIRCERA [Member] | Feb. 29, 2012 Roche [Member] MIRCERA [Member] Performance-based Milestone Payments [Member] | Feb. 29, 2012 Roche [Member] MIRCERA [Member] Upfront Payment Arrangement [Member] | Dec. 31, 2013 Roche [Member] PEGASYS [Member] | Dec. 31, 2013 Roche [Member] PEGASYS and MIRCERA [Member] | Dec. 31, 2007 Bayer Healthcare LLC [Member] | Jun. 30, 2013 Bayer Healthcare LLC [Member] | Dec. 31, 2013 Bayer Healthcare LLC [Member] | Dec. 31, 2007 Bayer Healthcare LLC [Member] Performance-based Milestone Payments [Member] | Dec. 31, 2007 Bayer Healthcare LLC [Member] Upfront Payment Arrangement [Member] | Dec. 31, 2013 Affymax, Inc. [Member] OMONTYS [Member] | Dec. 31, 2010 Amgen, Inc. [Member] | Dec. 31, 2013 Amgen, Inc. [Member] | Dec. 31, 2013 Baxter Healthcare [Member] BAX 855 (Hemophilia) [Member] | Dec. 31, 2013 Baxter Healthcare [Member] BAX 855 (Hemophilia) [Member] Upfront Payment Arrangement [Member] | Dec. 31, 2013 Other Member [Member]
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones | $ 144.3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50.0 |  |  |  |  |  | $ 28.0 |  | $ 66.3
Received upfront and milestone payments |  |  |  |  |  |  |  |  |  | 125.0 |  |  |  |  | 31.0 |  |  | 22.0 | 5.0 |  |  |  |  |  | 20.0 | 40.0 |  | 50.0 |  |  | 4.0 |
Contingent payments receivable based on development events regulatory to be pursued and completed solely by others |  |  | 140.0 |  |  |  |  |  | 70.0 |  |  | 175.0 | 35.0 | 75.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development milestones achieved |  | 25.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10.0 |  |  |  |  |  |  |  |  |
Contingent repayments of payment received |  |  |  | 70.0 | 10.0 | 10.0 | 20.0 | 30.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued interest rate |  |  |  | 4.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reduction on non-U.S. royalty for repayment |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential reduction in US royalty rate for repayment |  |  |  |  |  |  |  |  |  |  | 2.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential reduction in royalties |  |  |  |  |  |  |  |  |  |  | 35.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 16.1 | 16.1 |  |  | 10.3 | 6.9 |  |  | 22.5 |  |  |  |  | 34.2 |  |  |
Expected consideration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 27.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration received for product delivered in 2013 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 18.6 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Performance milestone payments recorded as a liability to Bayer |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10.0 |  |  |  |  |  |  |  |  |  |
Deferred revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 6.7 |  |  |  |  |

X
- Definition Consideration received for product delivered. + References No definition available. + Details
Name: | nktr_ConsiderationReceivedForProductDelivered
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contingent payments receivable based on development events. + References No definition available. + Details
Name: | nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Estimated Annual Interest Rate + References No definition available. + Details
Name: | nktr_EstimatedAnnualInterestRate
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected consideration. + References No definition available. + Details
Name: | nktr_ExpectedConsideration
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Liability to reimburse Bayer for Phase 3 costs. + References No definition available. + Details
Name: | nktr_LiabilityToBayerForReimbursementOfCosts
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential development milestones. + References No definition available. + Details
Name: | nktr_PotentialDevelopmentMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential milestone repayments, principal amounts + References No definition available. + Details
Name: | nktr_PotentialMilestoneRepaymentsPrincipalAmounts
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Potential Reduced Royalty Rate Used To Repay Milestone + References No definition available. + Details
Name: | nktr_PotentialReducedRoyaltyRateUsedToRepayMilestone
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential Reduction In Future Royalty Payments To Repay Post Approval Studies + References No definition available. + Details
Name: | nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- Definition Potential royalty reduction on US sales to repay post-approval study if required + References No definition available. + Details
Name: | nktr_PotentialRoyaltyReductionOnUsSalesToRepayPostApprovalStudyIfRequired
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront and Milestone Payments Received Under License Agreement + References No definition available. + Details
Name: | nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration